ADASUVE Drug Patent Profile

Which patents cover Adasuve, and what generic alternatives are available?

Adasuve is a drug marketed by Nova Pneuma and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-one patent family members in six countries.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this compound. Additional details are available on the loxapine profile page.

DrugPatentWatch^® Generic Entry Outlook for Adasuve

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 23, 2026. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ADASUVE

International Patents:	21
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	13
Patent Applications:	4,963
Drug Prices:	Drug price information for ADASUVE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADASUVE
What excipients (inactive ingredients) are in ADASUVE?	ADASUVE excipients list
DailyMed Link:	ADASUVE at DailyMed

See drug prices for ADASUVE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ADASUVE

NDA:

022549

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ADASUVE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lee's Pharmaceutical Limited	Phase 3
University of Arkansas	Phase 4
Mount Sinai Hospital, Chicago	Phase 4

See all ADASUVE clinical trials

US Patents and Regulatory Information for ADASUVE

ADASUVE is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012		RX	Yes	Yes			Y

Expired US Patents for ADASUVE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012

EU/EMA Drug Approvals for ADASUVE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Ferrer Internacional S.A.	Adasuve	loxapine	EMEA/H/C/002400Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.	Authorised	no	no	no	2013-02-20

International Patents for ADASUVE

See the table below for patents covering ADASUVE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	365548
Austria	401063
Austria	401064
Austria	404173

Supplementary Protection Certificates for ADASUVE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1389098	C300609	Netherlands		PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1389098	CA 2013 00046	Denmark		PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
1389098	CR 2013 00046	Denmark		PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
1389098	1390040-2	Sweden		PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220

Last updated: June 22, 2026

ADASUVE market dynamics and financial trajectory (turning points, exclusivity, and competitive pressure)

Executive summary: ADASUVE (dexmedetomidine? no; it is dexmedetomidine? Actually ADASUVE is loxapine inhalation powder) is an acute-care branded product for agitation associated with schizophrenia or bipolar I disorder. Its market has been constrained by (1) narrow labeling, (2) inhalation-specific delivery and logistics, (3) safety and administration constraints tied to bronchospasm risk, and (4) competitive erosion from generics of loxapine formulations and shifts in acute agitation practice patterns. Financial trajectory is best characterized as mid-single-digit to low-double-digit annual branded revenue historically, followed by plateau and then contraction, driven by limited growth levers and periodic inventory and channel effects, with meaningful downside risk tied to patent/exclusivity sunsets and ongoing payer scrutiny.

What is ADASUVE (dexmedetomidine? loxapine) used for and why does that shape demand?

ADASUVE is an inhaled loxapine product used for rapid treatment of agitation in specified psychiatric conditions. Demand is dominated by emergency department (ED) and acute behavioral unit workflows where clinicians can administer inhaled medication quickly and observe patients for adverse respiratory events.

How does the indication narrow the addressable market

• Target setting: acute agitation episodes in schizophrenia or bipolar I disorder.
• Channel fit: EDs, inpatient psychiatric units, crisis stabilization units.
• Clinical gatekeeping: prescriber comfort with inhaled agents and adherence to administration guidance, including respiratory screening and observation protocols.

What practical constraints limit adoption

• Bronchospasm risk requires appropriate patient selection and readiness to manage respiratory adverse reactions.
• Inhalation powder administration requires staff training and correct device technique.
• Payer authorization can be more stringent for acute, narrow-indication specialty products.

What FDA label restrictions drive utilization and payer pushback for ADASUVE?

Regulatory and label constraints translate directly into formulary coverage decisions, especially in large health systems with standardized acute agitation pathways.

Common utilization frictions

• Need for monitoring post-dose.
• Requirements around respiratory status and management if bronchospasm occurs.
• Institutional protocol alignment: hospitals often prefer agents with broader “standing order” compatibility across units.

How label language affects contracting

• Contracting typically centers on acute agitation throughput and cost-per-controlled-agitation episode.
• Health plans negotiate for utilization management given the narrow episode-based usage.

How has ADASUVE revenue evolved over time: growth, plateau, and decline?

ADASUVE’s financial trajectory is tied to branded competition dynamics, hospital adoption cycles, and the durability of its exclusivity/patent estate around the inhalation product and relevant formulations or methods.

Trajectory pattern seen in acute-care specialty brands

• Early growth tends to come from ED and behavioral health adoption.
• Mid-cycle phases show plateau when formularies standardize preferred comparators.
• Late-cycle phases show contraction as generics and alternative regimens gain share, and when channel inventory normalizes.

Key revenue drivers

• Number of facilities using ADASUVE (net new accounts vs churn).
• Dosing per acute agitation episode (real-world dosing compliance).
• Net price after rebates and chargebacks under payer contracting.
• Supply consistency and device availability.

Key downside drivers

• Competitive substitution toward other acute agitation products (parenteral antipsychotics, benzodiazepine strategies, and other inhaled options where available).
• Contracting pressure as budgets tighten and outcomes data is benchmarked.

What competitive landscape pressures ADASUVE: other acute agitation treatments and generics?

ADASUVE competes in a therapeutics mix rather than a single product-to-product lane. Market share shifts when hospitals standardize ED agitation algorithms.

Where substitution comes from

• Antipsychotic-based acute agitation pathways that use parenteral administration.
• Institutional preference for agents that match broader medical staff comfort and less specialized delivery systems.

Generic substitution risk

• Loxapine has generic presence in multiple oral/other formats historically, which limits willingness to pay for branded inhaled loxapine unless payers accept differentiation.
• Even if inhaled-specific IP remains, cost pressure tends to favor lower-cost branded or generic alternatives when clinically acceptable.

Payer and system behavior

• Under pharmacy benefit management, ADASUVE faces scrutiny on cost-effectiveness per acute episode.
• Movement to tiering or prior authorization is typical for high-cost, narrow-label products once budgets tighten.

When does ADASUVE face exclusivity and patent expiration risk for generics or inhaled competitors?

Market dynamics turn on the timing of exclusivity and patent protection around:

1. The active ingredient use/formulation.
2. The specific inhalation delivery technology.
3. Dosing regimens and related method claims.
4. Manufacturing or particle properties enabling bioavailability.

What investors and legal teams monitor

• Orange Book listings for ADASUVE and whether they are listed as protecting the drug product, method of use, or formulation.
• Expiration and any pediatric exclusivity or patent term adjustment impacts.
• Paragraph IV filings and any associated litigation that can delay generic entry.

What happens at the protection cliff

• When the last relevant patent or exclusivity ends, generic entry likelihood rises and pricing pressure accelerates.
• Inhalation device-associated products can be more IP- and formulation-sensitive than simple oral products, but once entry barriers fall, payer switching is fast in acute-care settings.

What is the Orange Book status of ADASUVE (protections, patent types, and expiry timelines)?

The Orange Book status is the controlling map for generic entry risk. For ADASUVE, market impact depends on whether listed patents protect:

• Drug product/formulation (highest practical barrier).
• Method of use (can be avoided by label carve-outs).
• Device or delivery system components (often complex and can sustain exclusivity longer).

How to interpret Orange Book listings for market planning

• If multiple drug product patents expire on staggered dates, incremental generic launch timing can create “phase-in” volume losses.
• If method-of-use patents dominate, risk is more about label design and contractual decisions than direct formulation replication.

How strong is the patent estate for ADASUVE and what does that mean for future pricing?

Patent strength translates into pricing durability. A multi-patent estate covering inhaled formulations and performance characteristics can slow substitution and support higher net pricing.

Common outcomes in inhaled specialty products

• Strong drug-product/formulation protection delays inhaled generics.
• Even with protection in place, payers can still drive net price down through contracting and utilization management.

What weaker estates do

• If protection is sparse or limited to method-of-use claims, generics can enter with fewer structural constraints and pricing pressure intensifies.

What generic entry scenarios exist for ADASUVE (label carve-outs vs full substitution)?

Generic entry planning for inhaled loxapine generally splits into two paths:

1. Full substitution: same indication and comparable inhalation performance.
2. Partial substitution: generic launch with an approach that reduces method-of-use exposure or relies on label and formulary differences.

Launch risk by scenario

• Full substitution: fastest volume erosion, strongest pricing pressure.
• Partial substitution: slower share movement but still meaningful net price declines under payer negotiations.

How hospital formularies respond

• If formulary committees can substitute without significant workflow changes, switching accelerates.
• If device training and patient selection requirements increase operational friction, switching can be slower even after legal barriers fall.

What patent litigation affects ADASUVE market timing and generic competition?

Market timing often depends on whether generics trigger Paragraph IV challenges and whether settlements delay entry.

Litigation pathways that matter

• Court outcomes that uphold or invalidate key patents.
• Settlement agreements that include delayed launch and “carve-out” provisions for certain claims.

Financial effect

• A settlement that delays launch creates a protected revenue window.
• A faster-than-expected court win for the generic accelerates revenue decline.

Does ADASUVE face biosimilar-like dynamics, or is this a small-molecule competitive model?

ADASUVE is a small-molecule inhaled product, so it does not face biosimilar frameworks. Competition follows generic small-molecule dynamics tied to:

• formulation equivalence,
• inhalation performance,
• and Orange Book patent clearance.

How do manufacturing and supply chain issues influence ADASUVE sales and hospital trust?

Acute-care products can be sensitive to:

• device availability,
• production consistency,
• and batch-level performance that affects inhalation dosing uniformity.

What typically moves monthly sales

• Inventory builds ahead of expected demand.
• Backorders or production interruptions that force prescribers to switch to alternatives.
• Seasonal ED volumes that impact agitation presentations.

What are the commercial levers for ADASUVE to defend share (and where are the ceilings)?

In a constrained acute indication, growth is less about market expansion and more about penetration and retention.

Commercial defense levers

• Contracting strategies that align ADASUVE with acute agitation order sets.
• Facility-level training and protocol integration.
• Outcomes-driven evidence packages for formulary committees.

Ceilings

• Fixed addressable volume: acute agitation episodes are episodic and facility-dependent.
• Administration constraints and monitoring requirements cap throughput advantages.

How does ADASUVE compare with other branded and generic acute agitation options on cost and adoption?

Net pricing and formulary placement depend on:

• perceived speed of control,
• safety profile in real-world psychiatric settings,
• and total treatment episode cost (drug plus monitoring and staff time).

What tends to win in practice

• Agents that reduce time-to-control and minimize adverse events consistent with label.
• Delivery systems that fit hospital staffing models without training burden.

Key Takeaways

• ADASUVE’s market dynamics are driven by a narrow acute agitation indication and the operational constraints of inhaled administration with respiratory safety requirements.
• Revenue trajectory typically follows a late-cycle contraction pattern seen in branded inhaled specialty products as payer scrutiny intensifies and substitution options rise.
• The next major market inflection is tied to Orange Book protection cliffs for inhalation drug-product/formulation and related method claims, which govern the timing and likelihood of inhaled generic entry.
• Patent strength and any Paragraph IV litigation/settlement structure can materially affect the pace of volume loss and pricing compression.

FAQs

1. What claims in the Orange Book listings for ADASUVE most affect generic entry timing?
2. How do hospital respiratory screening and monitoring requirements change real-world uptake of inhaled loxapine products like ADASUVE?
3. What are the most likely generic launch strategies for inhaled loxapine after patent expiry: full label substitution vs label carve-outs?
4. How do payer contracting and prior authorization policies typically change net revenue for narrow-indication acute-care drugs like ADASUVE?
5. What supply chain or device-performance issues can most quickly shift clinicians to alternative acute agitation treatments?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (accessed via FDA Orange Book database).